Point of Care, Point of Commercialization
UC Davis joins Orgenesis’ point-of-care network to develop and commercialize cell and gene therapies in house
James Strachan | | Interview
What if research hospitals could fully develop and process cell and gene therapies themselves? This was the question posed by Vered Caplan, CEO at Orgenesis, in a 2019 issue of The Medicine Maker (1). She explained how the costs of cell and gene therapies could be reduced if there was no need to involve traditional biotech companies or commercial CMOs. To facilitate this, Orgenesis is building a network of hospitals around the world that are equipped to develop and process cell and gene therapies, called point of care (POCare).
The University of California, Davis, has recently joined the network (2). Here, we speak with Peter Molloy, Executive Vice President at Orgenesis, to find out more.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.